Selected research
Industry Research
Biosimilar Development Services Industry Research Report 2026
Market perspective
The global Biosimilar Development Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biosimilar Development Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biosimilar Development Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biosimilar Development Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biosimilar Development Services include 3P Bio, BioPharmaSpec, Charles River Laboratories, ICON, Intertek, JSR Life Sciences, Labcorp, Syneos Health and PPD Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biosimilar Development Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biosimilar Development Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biosimilar Development Services Market by Company
3P Bio
BioPharmaSpec
Charles River Laboratories
ICON
Intertek
JSR Life Sciences
Labcorp
Syneos Health
PPD Inc
Profacgen
Sartorius
SGS S.A.
Biosimilar Development Services Segment by Type
Insulin
Anti-Cancer Drugs
Others
Biosimilar Development Services Segment by Application
Cancer
Diabetes
Arthritis
Psoriasis
Neutropenia
Enzyme or Hormone Deficiency
Others
Biosimilar Development Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Development Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Development Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Development Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biosimilar Development Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Insulin
- Anti-Cancer Drugs
- Others
Applications
- Cancer
- Diabetes
- Arthritis
- Psoriasis
- Neutropenia
- Enzyme or Hormone Deficiency
- Others
Companies covered
- 3P Bio
- BioPharmaSpec
- Charles River Laboratories
- ICON
- Intertek
- JSR Life Sciences
- Labcorp
- Syneos Health
- PPD Inc
- Profacgen
- Sartorius
- SGS S.A.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biosimilar Development Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Insulin
- 2.2.3 Anti-Cancer Drugs
- 2.2.4 Others
- 2.3 Biosimilar Development Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Diabetes
- 2.3.4 Arthritis
- 2.3.5 Psoriasis
- 2.3.6 Neutropenia
- 2.3.7 Enzyme or Hormone Deficiency
- 2.3.8 Others
- 2.4 Assumptions and Limitations
3 Biosimilar Development Services Breakdown Data by Type
- 3.1 Global Biosimilar Development Services Historic Market Size by Type (2021-2026)
- 3.2 Global Biosimilar Development Services Forecasted Market Size by Type (2027-2032)
4 Biosimilar Development Services Breakdown Data by Application
- 4.1 Global Biosimilar Development Services Historic Market Size by Application (2021-2026)
- 4.2 Global Biosimilar Development Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biosimilar Development Services Market Perspective (2021-2032)
- 5.2 Global Biosimilar Development Services Growth Trends by Region
- 5.2.1 Global Biosimilar Development Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biosimilar Development Services Historic Market Size by Region (2021-2026)
- 5.2.3 Biosimilar Development Services Forecasted Market Size by Region (2027-2032)
- 5.3 Biosimilar Development Services Market Dynamics
- 5.3.1 Biosimilar Development Services Industry Trends
- 5.3.2 Biosimilar Development Services Market Drivers
- 5.3.3 Biosimilar Development Services Market Challenges
- 5.3.4 Biosimilar Development Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biosimilar Development Services Players by Revenue
- 6.1.1 Global Top Biosimilar Development Services Players by Revenue (2021-2026)
- 6.1.2 Global Biosimilar Development Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Biosimilar Development Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biosimilar Development Services Head Office and Area Served
- 6.4 Global Biosimilar Development Services Players, Product Type & Application
- 6.5 Global Biosimilar Development Services Manufacturers Established Date
- 6.6 Global Biosimilar Development Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biosimilar Development Services Market Size (2021-2032)
- 7.2 North America Biosimilar Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biosimilar Development Services Market Size by Country (2021-2026)
- 7.4 North America Biosimilar Development Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biosimilar Development Services Market Size (2021-2032)
- 8.2 Europe Biosimilar Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biosimilar Development Services Market Size by Country (2021-2026)
- 8.4 Europe Biosimilar Development Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biosimilar Development Services Market Size (2021-2032)
- 9.2 Asia-Pacific Biosimilar Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biosimilar Development Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biosimilar Development Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biosimilar Development Services Market Size (2021-2032)
- 10.2 South America Biosimilar Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biosimilar Development Services Market Size by Country (2021-2026)
- 10.4 South America Biosimilar Development Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biosimilar Development Services Market Size (2021-2032)
- 11.2 Middle East & Africa Biosimilar Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biosimilar Development Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biosimilar Development Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 3P Bio
- 12.1.1 3P Bio Company Information
- 12.1.2 3P Bio Business Overview
- 12.1.3 3P Bio Revenue in Biosimilar Development Services Business (2021-2026)
- 12.1.4 3P Bio Biosimilar Development Services Product Portfolio
- 12.1.5 3P Bio Recent Developments
- 12.2 BioPharmaSpec
- 12.2.1 BioPharmaSpec Company Information
- 12.2.2 BioPharmaSpec Business Overview
- 12.2.3 BioPharmaSpec Revenue in Biosimilar Development Services Business (2021-2026)
- 12.2.4 BioPharmaSpec Biosimilar Development Services Product Portfolio
- 12.2.5 BioPharmaSpec Recent Developments
- 12.3 Charles River Laboratories
- 12.3.1 Charles River Laboratories Company Information
- 12.3.2 Charles River Laboratories Business Overview
- 12.3.3 Charles River Laboratories Revenue in Biosimilar Development Services Business (2021-2026)
- 12.3.4 Charles River Laboratories Biosimilar Development Services Product Portfolio
- 12.3.5 Charles River Laboratories Recent Developments
- 12.4 ICON
- 12.4.1 ICON Company Information
- 12.4.2 ICON Business Overview
- 12.4.3 ICON Revenue in Biosimilar Development Services Business (2021-2026)
- 12.4.4 ICON Biosimilar Development Services Product Portfolio
- 12.4.5 ICON Recent Developments
- 12.5 Intertek
- 12.5.1 Intertek Company Information
- 12.5.2 Intertek Business Overview
- 12.5.3 Intertek Revenue in Biosimilar Development Services Business (2021-2026)
- 12.5.4 Intertek Biosimilar Development Services Product Portfolio
- 12.5.5 Intertek Recent Developments
- 12.6 JSR Life Sciences
- 12.6.1 JSR Life Sciences Company Information
- 12.6.2 JSR Life Sciences Business Overview
- 12.6.3 JSR Life Sciences Revenue in Biosimilar Development Services Business (2021-2026)
- 12.6.4 JSR Life Sciences Biosimilar Development Services Product Portfolio
- 12.6.5 JSR Life Sciences Recent Developments
- 12.7 Labcorp
- 12.7.1 Labcorp Company Information
- 12.7.2 Labcorp Business Overview
- 12.7.3 Labcorp Revenue in Biosimilar Development Services Business (2021-2026)
- 12.7.4 Labcorp Biosimilar Development Services Product Portfolio
- 12.7.5 Labcorp Recent Developments
- 12.8 Syneos Health
- 12.8.1 Syneos Health Company Information
- 12.8.2 Syneos Health Business Overview
- 12.8.3 Syneos Health Revenue in Biosimilar Development Services Business (2021-2026)
- 12.8.4 Syneos Health Biosimilar Development Services Product Portfolio
- 12.8.5 Syneos Health Recent Developments
- 12.9 PPD Inc
- 12.9.1 PPD Inc Company Information
- 12.9.2 PPD Inc Business Overview
- 12.9.3 PPD Inc Revenue in Biosimilar Development Services Business (2021-2026)
- 12.9.4 PPD Inc Biosimilar Development Services Product Portfolio
- 12.9.5 PPD Inc Recent Developments
- 12.10 Profacgen
- 12.10.1 Profacgen Company Information
- 12.10.2 Profacgen Business Overview
- 12.10.3 Profacgen Revenue in Biosimilar Development Services Business (2021-2026)
- 12.10.4 Profacgen Biosimilar Development Services Product Portfolio
- 12.10.5 Profacgen Recent Developments
- 12.11 Sartorius
- 12.11.1 Sartorius Company Information
- 12.11.2 Sartorius Business Overview
- 12.11.3 Sartorius Revenue in Biosimilar Development Services Business (2021-2026)
- 12.11.4 Sartorius Biosimilar Development Services Product Portfolio
- 12.11.5 Sartorius Recent Developments
- 12.12 SGS S.A.
- 12.12.1 SGS S.A. Company Information
- 12.12.2 SGS S.A. Business Overview
- 12.12.3 SGS S.A. Revenue in Biosimilar Development Services Business (2021-2026)
- 12.12.4 SGS S.A. Biosimilar Development Services Product Portfolio
- 12.12.5 SGS S.A. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst